Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
Dow Jones opens higher but Nasdaq dips into red, as jobs and CPI eyed
05:00am, Thursday, 12'th Feb 2026
10am: Dow opens higher, Nasdaq dips US stocks have made another uneven start. The Dow Jones and S&P 500 have opened 0.4% and 0.2% higher, but the Nasdaq...
BioVie could offer first new Parkinson's therapy in decades
10:35am, Wednesday, 11'th Feb 2026
In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharma
BioVie hits enrolment milestone in early Parkinson's trial, data due later this year
09:27am, Friday, 16'th Jan 2026
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disea
BioVie (NASDAQ:BIVI) Stock Price Down 4.7% – Should You Sell?
02:28am, Thursday, 15'th Jan 2026
BioVie Inc. (NASDAQ: BIVI - Get Free Report) dropped 4.7% during trading on Wednesday. The company traded as low as $1.21 and last traded at $1.21. Approximately 79,581 shares were traded during mid-d
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
02:05pm, Wednesday, 24'th Dec 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inve
Indus Gas shares halve in value as it seeks AIM exit door
04:04am, Monday, 22'nd Dec 2025
Indus Gas (LSE:INDI) shares lost more than half their value after announcing plans to cancel its listing on AIM. The company, in a statement, cited limited...
BioVie advances lead drug candidates - ICYMI
08:05am, Saturday, 20'th Dec 2025
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do talked with Proactive about the company's recent developments in its two lead drug candidates: Bezisterim and BIV201. Bezisterim, which blocks TNF a
BioVie advances lead drug candidates - ICYMI
02:37am, Saturday, 20'th Dec 2025
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do talked with Proactive about the company’s recent developments in its two lead drug candidates:...
What Makes BioVie (BIVI) a New Buy Stock
01:01pm, Thursday, 11'th Dec 2025
BioVie (BIVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9
08:00am, Wednesday, 19'th Nov 2025
CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
08:20am, Friday, 24'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioVie Inc. (NASDAQ: BIVI) breached their fiduciary duties to share
BioVie Inc. - Special Call
06:56pm, Wednesday, 08'th Oct 2025
BioVie Inc. - Special Call Company Participants Cuong Viet Do - President, CEO & Director Conference Call Participants Craig Brelsford Presentation Craig Brelsford Hello. This is Craig Brelsford with
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
08:00am, Friday, 26'th Sep 2025
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue
